Source comparison
Sleep Architecture Changes: REM vs Slow-Wave Distribution
MK-677 alters the distribution of sleep stages in a predictable pattern: increased slow-wave sleep (stages 3 and 4) and delayed but more consolidated REM sleep. Polysomnography data from the original 1997 clinical trial showed that stage 4 sleep increased from
This comparison does not assign a generated winner or score.
- MK-677 alters the distribution of sleep stages in a predictable pattern: increased slow-wave sleep (stages 3 and 4) and delayed but more consolidated REM sleep. Polysomnography data from the original 1997 clinical trial showed that stage 4 sleep increased from a baseline mean of 8% to 12% of total sleep time, while stage 2 (light sleep) decreased from 56% to 48%. REM sleep percentage remained stable at approximately 20–22% of total sleep time, but REM onset latency increased by an average of 18 minutes. Meaning subjects entered REM sleep later but experienced longer, uninterrupted REM episodes once initiated.
- This redistribution matters because slow-wave sleep and REM sleep serve different restorative functions. Slow-wave sleep is when the brain clears metabolic waste via the glymphatic system, consolidates declarative memory, and downregulates cortisol production. REM sleep handles emotional regulation, procedural memory consolidation, and neural plasticity. Most sleep aids (particularly GABA agonists like zolpidem or benzodiazepines) increase total sleep time but suppress REM sleep and reduce SWS depth. Creating a pharmacological sleep state that doesn't deliver the same restorative benefits as natural sleep architecture. MK-677 is mechanistically different: it enhances the deepest phase of sleep without suppressing REM, though it does shift REM onset later in the night.
- The practical implication: users typically report feeling more physically restored upon waking (a slow-wave sleep benefit) but may not experience the same improvement in mood or emotional regulation (REM-dependent processes). Some users report more vivid dreams, which aligns with the data showing longer, more consolidated REM episodes. The delayed REM onset can be problematic for individuals who wake frequently during the night. If you wake before reaching REM sleep, you lose that cycle's REM contribution entirely.
- Dosing timing influences this distribution. The 1997 study administered MK-677 30–60 minutes before bed, which maximized the first nocturnal GH pulse and corresponded with the largest increases in stage 4 sleep. Administering MK-677 earlier in the evening (3–4 hours before bed) reduced the magnitude of slow-wave sleep enhancement because the peak GH pulse occurred before sleep onset. The compound has a half-life of approximately 4–6 hours, so timing the dose to align peak plasma concentration with the first 90-minute sleep cycle is essential for optimal deep sleep optimization.